| Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 121-130, 2019 | 2668 | 2019 |
| Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome Z Punthakee, R Goldenberg, P Katz Canadian journal of diabetes 42, S10-S15, 2018 | 1287 | 2018 |
| Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 131-138, 2019 | 617 | 2019 |
| Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial S Verma, CD Mazer, AT Yan, T Mason, V Garg, H Teoh, F Zuo, A Quan, ... Circulation 140 (21), 1693-1702, 2019 | 559 | 2019 |
| Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome R Goldenberg, Z Punthakee Canadian journal of diabetes 37, S8-S11, 2013 | 510 | 2013 |
| SGLT2 inhibitor–associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis RM Goldenberg, LD Berard, AYY Cheng, JD Gilbert, S Verma, VC Woo, ... Clinical therapeutics 38 (12), 2654-2664. e1, 2016 | 342 | 2016 |
| Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone T Forst, R Guthrie, R Goldenberg, J Yee, U Vijapurkar, G Meininger, ... Diabetes, Obesity and Metabolism 16 (5), 467-477, 2014 | 338 | 2014 |
| Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease CD Mazer, GMT Hare, PW Connelly, RE Gilbert, N Shehata, A Quan, ... Circulation 141 (8), 704-707, 2020 | 325 | 2020 |
| Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case … FM Sacks, MP Hermans, P Fioretto, P Valensi, T Davis, E Horton, ... Circulation 129 (9), 999-1008, 2014 | 312 | 2014 |
| Pharmacologic management of type 2 diabetes W Harper, M Clement, R Goldenberg, A Hanna, A Main, R Retnakaran, ... Canadian Journal of Diabetes 37, S61-S68, 2013 | 258 | 2013 |
| Pharmacologic glycemic management of type 2 diabetes in adults L Lipscombe, G Booth, S Butalia, K Dasgupta, DT Eurich, R Goldenberg, ... Canadian journal of diabetes 42, S88-S103, 2018 | 239 | 2018 |
| Once-weekly insulin for type 2 diabetes without previous insulin treatment J Rosenstock, HS Bajaj, A Janež, R Silver, K Begtrup, MV Hansen, T Jia, ... New England Journal of Medicine 383 (22), 2107-2116, 2020 | 211 | 2020 |
| Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study P Fioretto, S Del Prato, JB Buse, R Goldenberg, F Giorgino, D Reyner, ... Diabetes, Obesity and Metabolism 20 (11), 2532-2540, 2018 | 188 | 2018 |
| Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal‐P) M Pinget, R Goldenberg, E Niemoeller, I Muehlen‐Bartmer, H Guo, ... Diabetes, Obesity and Metabolism 15 (11), 1000-1007, 2013 | 166 | 2013 |
| Screening for diabetes in adults JM Ekoe, R Goldenberg, P Katz, ... Canadian journal of diabetes 42, S16-S19, 2018 | 158 | 2018 |
| Semaglutide: review and place in therapy for adults with type 2 diabetes RM Goldenberg, O Steen Canadian journal of diabetes 43 (2), 136-145, 2019 | 101 | 2019 |
| Screening for type 1 and type 2 diabetes JM Ekoé, Z Punthakee, T Ransom, APH Prebtani, R Goldenberg Canadian journal of diabetes 37, S12-S15, 2013 | 100 | 2013 |
| Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial EA Bohula, BM Scirica, SE Inzucchi, DK McGuire, AC Keech, SR Smith, ... The Lancet 392 (10161), 2269-2279, 2018 | 96 | 2018 |
| Pharmacologic management of type 2 diabetes: 2016 interim update G Booth, L Lipscombe, S Butalia, K Dasgupta, D Eurich, R Goldenberg, ... Canadian Journal of Diabetes 40 (6), 484-486, 2016 | 89 | 2016 |
| Sodium‐glucose co‐transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: the STOP DKA protocol RM Goldenberg, JD Gilbert, IM Hramiak, VC Woo, B Zinman Diabetes, Obesity and Metabolism 21 (10), 2192-2202, 2019 | 87 | 2019 |